PDF / 67 KB 
collectBayerNews_20090212_0037_en.pdf BayerNews_20090212_0037_en.pdf
Berlin, February 12, 2009 - Bayer Schering Pharma AG, the pharmaceutical
division of Bayer HealthCare (BHC), announced today that it will be
strengthening its global Research and Development (R&D) capabilities through
the foundation of a global R&D center in Beijing, China. The company will
invest some 100 million Euro over the next five years to establish the center.
With the establishment of the R&D center in China, especially Asian patients
will benefit from considering their clinical profile and medical needs early-on.
"We are continuously increasing our presence in the Asia Pacific Region where
China is our key growth driver. In our new R&D Center in Beijing, we will
establish a world class R&D team extending our global R&D expertise and
capabilities," said Andreas Fibig, Executive Committee member of BHC and
Chairman of Bayer Schering Pharma AG's Board of Management. "Beijing will be an
important site for our global innovative drug development."
According to IMS Health, Bayer is the number one healthcare company in China
and the growth rate in China was around 43% in 2007. China is the third largest
market worldwide for the Bayer group, and it will become the third country
besides Germany and the US to host a Global R&D Center for Bayer Schering
Pharma. Highly talented scientific teams will cooperate in Beijing focusing on
the development of innovative therapies.
"Our goal is to build a world class organization here in Beijing that will lead
drug development not only for China but also for other Asian countries." said
Kemal Malik, member of the Board of Management of Bayer Schering Pharma AG,
Head of Global Development and Chief Medical Officer. "Our aim is to
systematically include Asian patients earlier in global drug development,
breaking the tradition of 'US and EU first'."
Bayer Schering Pharma AG is a worldwide leading specialty pharmaceutical
company focusing on women's healthcare, cardiology, oncology and diagnostic
imaging. It possesses high competence in these therapeutic areas with a strong
development pipeline.
"Constantly improving the quality and output of research is crucial for a
pharmaceutical company to bring novel therapies to patients." said Andreas
Busch, member of the Board of Management of Bayer Schering Pharma AG, Head of
Global Drug Discovery. "We believe that China bears tremendous potential in
terms of innovation. In addition to the establishment of development functions,
we will also launch the Global Drug Discovery Innovation Center here in Beijing
where our scientists will expedite new innovative approaches together with our
Chinese partners. By doing so, we also want to support the further development
of local expertise."
Along this line, Bayer Schering Pharma also announced that it is currently in
advanced discussions with Tsinghua University on entering into a unique
strategic partnership to pursue research collaborations for the discovery of
new disease-related targets in the core areas of Bayer's pharmaceutical
research. With this partnership Bayer would be the first multinational company
in China to enter into a partnership with such a respected and renowned Chinese
university.
"China is home to a large pool of skilled medical and scientific talents. Our
goal is to work closely together with our Chinese partners to support China
conducting their own R&D activities and at the same time we will be able to
strengthen our own R&D capabilities," said Andreas Fibig.
About Bayer
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen,
Germany.The company combines the global activities of the Animal Health,
Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals
business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's
aim is to discover and manufacture products that will improve human and animal
health worldwide. Find more information at www.bayerhealthcare.com.
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, Special Medicines, General Medicine and Women's Healthcare.
With innovative products, Bayer Schering Pharma aims for leading positions in
specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to
make a contribution to medical progress and strives to improve the quality of
life. Find more information at www.bayerscheringpharma.de.
